透景生命(300642) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥74,893,130.45, a decrease of 19.53% compared to ¥93,072,134.17 in the same period last year[4] - Net profit attributable to shareholders was ¥471,691.09, representing a significant increase of 110.51% from a loss of ¥4,487,874.40 in the previous year[4] - Basic and diluted earnings per share improved to ¥0.0029 from a loss of ¥0.0277, marking an increase of 110.47%[4] - The company reported a net loss of CNY 924,238.20 for the quarter, compared to a net loss of CNY 6,039,882.63 in the same quarter last year[22] - Total operating revenue for Q1 2025 was CNY 74,893,130.45, a decrease of 19.5% compared to CNY 93,072,134.17 in the same period last year[21] Cash Flow - The net cash flow from operating activities decreased by 43.73% to ¥16,411,586.68 from ¥29,166,783.93 in the previous year[12] - Cash received from sales of goods and services was CNY 90,762,733.09, down 22.5% from CNY 117,217,781.20 in the previous year[24] - The company's cash flow from operating activities included CNY 7,172,358.43 received from other operating activities, compared to CNY 6,554,075.76 in the previous year[24] - Operating cash inflow totaled $98,014,465.76, a decrease from $123,956,954.51 in the previous period[25] - Net cash flow from operating activities was $16,411,586.68, down from $29,166,783.93[25] Investment Activities - Investment activities generated a net cash flow of ¥65,197,109.34, a significant increase from a negative cash flow of ¥45,294,002.32 in the same period last year, reflecting a 243.94% change[12] - Investment cash inflow increased to $183,479,343.73 from $103,421,362.39, primarily due to cash received from investment recoveries[25] - Net cash flow from investment activities was $65,197,109.34, a significant improvement from a negative $45,294,002.32[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,690,994,722.29, down 3.32% from ¥1,748,986,409.73 at the end of the previous year[4] - Total current assets decreased from 918,716,063.66 yuan to 877,362,845.65 yuan, a decline of approximately 4.6%[18] - Total liabilities decreased to CNY 174,638,902.26 from CNY 230,944,723.47, a reduction of 24.4%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,040[14] - The largest shareholder, Yao Jian'er, holds 20.09% of shares, totaling 32,753,700 shares, with 7,100,000 shares pledged[14] - The second largest shareholder, Lingfei Group Co., Ltd., holds 7.38% of shares, totaling 12,035,800 shares, with 10,180,000 shares pledged[14] Research and Development - The company reported a 36.01% reduction in R&D expenses, totaling ¥11,057,969.71 compared to ¥17,281,879.24 in the previous year[11] - Research and development expenses were CNY 11,057,969.71, a decrease of 36.2% from CNY 17,281,879.24 year-over-year[21] Cash and Equivalents - Cash and cash equivalents increased from 308,738,859.31 yuan to 391,089,370.79 yuan, an increase of approximately 26.7%[18] - The ending balance of cash and cash equivalents stood at $385,908,970.79, compared to $365,101,536.86 at the end of the previous period[25] - The net increase in cash and cash equivalents was $88,350,511.48, contrasting with a decrease of $15,575,692.83 previously[25]